Your session is about to expire
← Back to Search
Vemurafenib + Copanlisib for Thyroid Cancer
Study Summary
This trial is studying a new drug combo to treat BRAF-mutant thyroid cancers & increase sensitivity to radioiodine therapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can swallow pills without any major stomach or intestine problems.I have tissue samples from my cancer available for study.I am not using highly effective birth control methods.I take medication for seizures.I am a man and will use a condom during treatment and for 6 months after.You have a positive test for cytomegalovirus (CMV) at the start of the study.I have a history of bleeding disorders or unexplained bleeding.I am mostly able to care for myself and carry out daily activities.My condition is resistant to standard treatments.My tumor has a BRAF V600 mutation.Your test results meet certain requirements.I cannot follow a low-iodine diet or need medication high in iodide.I have been diagnosed with HIV.I have brain tumors that have not been treated.I was diagnosed and treated for another cancer within the last 2 years.I am not taking any medications that are not allowed in this study.My thyroid cancer is confirmed and originates from follicular cells.I have a wound, ulcer, or bone fracture that hasn't healed.People with certain heart and blood sugar problems.I haven't received thyroid cancer treatment recently.I have not had a clot or embolism recently.I am taking more than 15 mg of prednisone or its equivalent daily.I do not have any serious infections.I have a lung condition or my lungs don’t work very well.You have hepatitis B or C virus infection.My cancer can be measured by scans and has grown after radiation.I am 18 years old or older.
- Group 1: Participants with thyroid cancer
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the typical indications for Copanlisib treatment?
"Copanlisib is frequently prescribed as a remedy for Erdheim-Chester Disease. It has also been used to address metastatic melanoma, non-small cell lung carcinoma, lymphomas and various cases of follicular malignancy."
What is the upper bound on participants for this experiment?
"Affirmative. Clinicaltrials.gov provides evidence to suggest that this clinical trial is actively seeking participants, which was first posted on June 26th 2020 and most recently edited on March 3rd 2022. It requires 32 patients from 7 enrolment sites."
What are the current regulatory opinions regarding Copanlisib?
"Although limited studies have been conducted to assess its safety and efficacy, Copanlisib received a score of 1 on our scale."
What other research initiatives have been undertaken examining Copanlisib's effects?
"In 2012, Copanlisib's clinical use first began at James Graham Brown Cancer Center-University of Louisville. Since then there have been 71 completed trials and 74 ongoing studies, the majority originating from Harrison New jersey."
Are additional participants being sought out for this research endeavor?
"Clinicaltrials.gov currently indicates that the trial is recruiting patients, which began on June 26th 2020 and was revised March 3rd 2021."
Could you provide a list of the medical centers running this clinical research in our city?
"Presently, the clinical trial has 7 operational sites located in Harrison, Basking Ridge and Commack as well as other cities. To reduce travel expenses associated with enrolment, it is beneficial to select a clinic closest to you."
Share this study with friends
Copy Link
Messenger